LifeVantage Corp ( (LFVN) ) has realeased its Q1 earnings. Here is a breakdown of the information LifeVantage Corp presented to its investors.
LifeVantage Corporation is a health and wellness company specializing in nutrigenomics, offering products designed to optimize health at the cellular level. The company recently reported its financial results for the first quarter of fiscal 2025, highlighting a decrease in revenue but improvements in profitability metrics.
For the first quarter, LifeVantage reported a revenue of $47.2 million, marking an 8.1% decline from the previous year. This decrease was attributed to foreign currency fluctuations and reduced revenue in both the Americas and Asia/Pacific & Europe regions. Despite the revenue drop, the company’s net income per diluted share saw a significant rise to $0.14 from $0.05 in the previous year, and adjusted EBITDA increased to $4.4 million from $4.0 million.
Key performance indicators included an 11% increase in adjusted EBITDA and a decrease in SG&A expenses as a percentage of revenue. Additionally, LifeVantage launched the MindBody GLP-1 System™, aiming to expand its market reach and capture the weight management segment. The launch has been met with positive initial responses from customers and consultants.
Looking ahead, LifeVantage maintains its fiscal year 2025 guidance, expecting revenue between $200 million to $210 million and adjusted EBITDA between $18 million to $21 million. The company is optimistic about future growth, supported by a strategic focus on cost optimization and innovation investment.
